Global apheresis market led by Fresenius Medical Care, Cerus and Haemonetics

The global apheresis market has been forecast to increase at a compound annual growth rate (CAGR) of 11% over the next five years, increasing from a valuation of $1,140.8 million in 2012, to hit a market value of $1,922.4 million.

The global apheresis market is based on a process which uses various technologies and leverage platforms to collect blood, and then to separate it into different components using centrifugation and membrane separation technology.

The market is presently mature, primarily due to the apprehensions of vendors to infuse funds to further develop new applications. Nevertheless, with new opportunities unfolding for materials, services and apheresis technology devices, investments are likely to flow in.

Further, with medical insurance companies customising their reimbursement policies as per the treated conditions, the high cost of therapeutic apheresis is not likely to hamper market growth.

Although therapeutic apheresis is safe and effective, several users are ignorant of this therapy, and those suffering from chronic diseases go for conventional therapies, presuming it to be the best form of treatment.

Even though some patients are aware, they have their own incorrect perceptions that prevent them from adopting apheresis therapy, which eventually restrain market growth.

Key players in the global apheresis market have adopted various strategies to expand their global footprint and increase market share. New product developments; agreements, partnerships and collaborations; mergers and acquisitions; and expansion are some of the major strategies adopted by players to achieve growth

Agreements, collaborations, joint ventures and partnerships accounted for 42% of the key growth strategies by key players such as Fresenius Medical Care AG (Germany), Cerus Corporation (US), and Haemonetics Corporation (US).

For example, in April 2012, Cerus Corporation signed a supply agreement with King Faisal Specialist Hospital, a Saudi Arabia based blood service provider. The agreement allowed the hospital to use the INTERCEPT Blood System to treat its platelet production of around 5,600 units per year.

For more information on the global apheresis market, see the latest research: Global Apheresis Market

Follow us on Twitter @CandMResearch